Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

RDX-002, a novel iMTP inhibitor, showed promising results in a Ph2 study, reducing blood fat and weight regain after GLP-1 ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Eli Lilly is now selling Mounjaro GLP-1 weight loss drugs in India. Rival Novo Nordisk began Indian Wegovy sales in June.